Brief: Mesoblast Says HY Loss Attributable $47.9 Million
27/02/2025 01:17
Feb 27 (Reuters) - Mesoblast Ltd MSB.AX: HY LOSS ATTRIBUTABLE $47.9 MILLION HY REVENUE $3.2 MILLION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil